Nio Y, Ohgaki K, Tsuchitani T, Imai S, Shiraishi T, Tobe T
Division of Surgical Oncology, Faculty of Medicine, Kyoto University, Japan.
Biotherapy. 1990;2(3):213-22. doi: 10.1007/BF02173522.
A streptococcal preparation, OK-432, was orally administered at a dose of 5 KE to patients with gastric or colorectal cancer for 7-14 days before their operations, and its immunomodulatory effects on peripheral blood lymphocytes (PBL), regional node lymphocytes (RNL) and tumor infiltrating lymphocytes (TIL) were assessed. The group treated with OK-432 included 8 gastric and 6 colorectal cancer patients, and the control group included 8 gastric and 8 colorectal cancer patients. The NK cell activity of PBL was significantly augmented by the oral administration of OK-432, and the proportions of Leu 7+ and Leu 11+ cells in PBL also increased. The responses of PBL and TIL to autologous tumor extracts in the presence of interleukin-2 were enhanced after the oral administration of OK-432. The proportion of OKT8+ cells in PBL increased after treatment with oral OK-432, whereas the proportion in RNL significantly decreased. These results indicate that oral OK-432 affects NK and T cells and may augment the antitumor immunity of patients with gastrointestinal cancer.
一种链球菌制剂OK-432，在胃癌或结直肠癌患者手术前，以5KE的剂量口服给药7至14天，评估其对外周血淋巴细胞（PBL）、区域淋巴结淋巴细胞（RNL）和肿瘤浸润淋巴细胞（TIL）的免疫调节作用。接受OK-432治疗的组包括8例胃癌患者和6例结直肠癌患者，对照组包括8例胃癌患者和8例结直肠癌患者。口服OK-432可显著增强PBL的NK细胞活性，PBL中Leu 7+和Leu 11+细胞的比例也增加。口服OK-432后，在白细胞介素-2存在的情况下，PBL和TIL对自体肿瘤提取物的反应增强。口服OK-432治疗后，PBL中OKT8+细胞的比例增加，而RNL中的比例显著下降。这些结果表明，口服OK-432会影响NK细胞和T细胞，并可能增强胃肠道癌患者的抗肿瘤免疫力。
